BioXcel Therapeutics, Inc. (BTAI)
Market Cap | 805.53M |
Revenue (ttm) | 137,000 |
Net Income (ttm) | -137.07M |
Shares Out | 28.02M |
EPS (ttm) | -4.88 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 121,768 |
Open | 28.29 |
Previous Close | 28.52 |
Day's Range | 27.57 - 28.88 |
52-Week Range | 8.80 - 32.96 |
Beta | 1.15 |
Analysts | Buy |
Price Target | 48.59 (+69.07%) |
Earnings Date | Mar 9, 2023 |
About BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acu... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $48.59, which is an increase of 69.07% from the latest price.
News

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC

BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer's Disease
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer's patients in nursing homes with moderate to severe dementia

BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
IGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medic...

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran...

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop trans...

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer's Disease
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identi...

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority
Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development

4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD
Microsoft, Twitter, BioXcel Therapeutics and Pioneer Natural Resources were our top stock trades for Thursday. Here's the trade now.

Why BioXcel Therapeutics Stock Is Surging Today
BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for...